Appendix 1. Possible equity extension items for STROBE.

Section	Item No	Standard STROBE Checklist	Possible issues for STROBE equity extension (based on PRISMA-Equity and CONSORT-Equity reporting items)
Title and abstract	1		
		1a. Indicate the study's design with a commonly used term in the title or the abstract	
		1b. Provide in the abstract an informative and balanced summary of what was done and what was found	- Describe population according to PROGRESS-Plus - Describe extent/limits of applicability to populations of interest across PROGRESS-Plus characteristics
Background/ rationale	2		
		2. Explain the scientific background and rationale for the investigation being reported	- If equity is a focus, what is the rationale for focus on health equity?
Objectives	3		
		3. State specific objectives, including any pre specified hypotheses	
Methods			
Study design	4		
		4. Present key elements of study design early in the paper	- Report who was involved/engaged/consulted in study design (e.g. patients, community, industry, government, etc.) - Report whether a theory of change was described for the study to design analysis
Setting	5		
		5. Describe the setting, locations, and relevant dates, including periods of recruitment, exposure, follow-up, and data collection	- Report whether methods of sampling/recruitment were designed to reach populations across relevant PROGRESS-Plus characteristics - Is there possibility of self-selection bias across PROGRESS-Plus factors?
Participants	6		
		6a. *Cohort study*—Give the eligibility criteria, and the sources and methods of selection of participants. Describe methods of follow-up *Case-control study*—Give the eligibility criteria, and the sources and methods of case ascertainment and control selection. Give the rationale for the choice of cases and controls *Cross-sectional study*—Give the eligibility criteria, and the sources and methods of selection of participants	- Give inclusion and exclusion criteria across relevant PROGRESS-Plus characteristics - Report context and relationship to health equity (additional items may be needed to document context and systems in which the studies take place) - Report details of partnerships with populations and communities, where applicable

Section	Item No	Standard STROBE Checklist	Possible issues for STROBE equity extension (based on PRISMA-Equity and CONSORT-Equity reporting items)
		6b. *Cohort study*—For matched studies, give matching criteria and number of exposed and unexposed *Case-control study*—For matched studies, give matching criteria and the number of controls per case	- Report whether any PROGRESS-Plus factors used for matching, how categories were determined and why
Variables	7		
		7. Clearly define all outcomes, exposures, predictors, potential confounders, and effect modifiers. Give diagnostic criteria, if applicable	- Report whether outcomes were identified as relevant and important to populations across PROGRESS-Plus
Data sources/ measurement	8		
		8.* For each variable of interest, give sources of data and details of methods of assessment (measurement). Describe comparability of assessment methods if there is more than one group	- Report the method of obtaining population characteristics (e.g. age)
Bias	9		
		9. Describe any efforts to address potential sources of bias	- Report efforts to reduce selection bias across PROGRESS-Plus - Report whether dimensions of context might influence the study (e.g. bias in response/participation)
Study size	10		
		1No. Explain how the study size was arrived at	- Report whether PROGRESS-Plus characteristics of interest were considered in determining the study size
Quantitative variables	11		
		11. Explain how quantitative variables were handled in the analyses. If applicable, describe which groupings were chosen and why	- Report how decisions were made about analyses related to PROGRESS-Plus, including whether any categories were defined, and how they were decided - Report whether dimensions of context were collected for analysis
ETHICAL CONCERNS	--	--	New item in CONSORT-Equity, may be relevant to STROBE-Equity
			- Report details of informed consent and ethical clearance
Statistical methods	12		
		12a. Describe all statistical methods, including those used to control for confounding	- If PROGRESS-Plus factors used to control for confounding, describe how they were defined and rationale - Report whether contextual factors were used in adjustment for confounding
		12b. Describe any methods used to examine subgroups and interactions	- Report details of additional analyses related to health equity - Report whether context or systems were explored
		12c. Explain how missing data were addressed	- Explain whether missing data was related to individual or contextual factors associated with health inequities

Section	Item No	Standard STROBE Checklist	Possible issues for STROBE equity extension (based on PRISMA-Equity and CONSORT-Equity reporting items)
		12d. *Cohort study*—If applicable, explain how loss to follow-up was addressed *Case-control study*—If applicable, explain how matching of cases and controls was addressed *Cross-sectional study*—If applicable, describe analytical methods taking account of sampling strategy	
		12e. Describe any sensitivity analyses	
Results			
Participants	13		
		13a.* Report numbers of individuals at each stage of study—e.g. numbers potentially eligible, examined for eligibility, confirmed eligible, included in the study, completing follow-up, and analyzed	
		13b.* Give reasons for non-participation at each stage	- Describe the losses and exclusions of participants across PROGRESS-Plus - Describe non-response/non-participation across PROGRESS-Plus
		13c.* Consider use of a flow diagram	
Descriptive data	14		
		14a.* Give characteristics of study participants (e.g. demographic, clinical, social) and information on exposures and potential confounders	- Present characteristics across relevant PROGRESS-Plus characteristics
		14b.* Indicate number of participants with missing data for each variable of interest	- Describe whether data on PROGRESS-Plus factors are missing (e.g. ethnicity data in some settings has a high level of missing-ness)
		14c.* *Cohort study*—Summaries follow-up time (e.g., average and total amount)	
Outcome data	15		
		15.* *Cohort study*—Report numbers of outcome events or summary measures over time	
		Case-control study—Report numbers in each exposure category, or summary measures of exposure	
		Cross-sectional study—Report numbers of outcome events or summary measures	
Main results	16		

Section	Item No	Standard STROBE Checklist	Possible issues for STROBE equity extension (based on PRISMA-Equity and CONSORT-Equity reporting items)
		16a. Give unadjusted estimates and, if applicable, confounder-adjusted estimates and their precision (e.g., 95% confidence interval). Make clear which confounders were adjusted for and why they were included	- Report if confounders were defined for contextual or PROGRESS-Plus factors that are associated with health inequities - Justify why certain categories of PROGRESS-Plus are not disaggregated for analysis
		16b. Report category boundaries when continuous variables were categorized	- Justify any categories used across PROGRESS-Plus characteristics
		16c. If relevant, consider translating estimates of relative risk into absolute risk for a meaningful time period	
Other analysis	17		
		17. Report other analyses done—e.g. analyses of subgroups and interactions, and sensitivity analyses	- Report other analyses to address health equity questions, if the study had objectives related to health equity
Discussion			
Key results	18		
		18. Summaries key results with reference to study objectives	
Limitations	19		
		19. Discuss limitations of the study, taking into account sources of potential bias or imprecision. Discuss both direction and magnitude of any potential bias	
Interpretation	20		
		20a. Give a cautious overall interpretation of results considering objectives, limitations, multiplicity of analyses, results from similar studies, and other relevant evidence	- Consider importance of context in interpretation of health equity
Generalizability	21		
		21. Discuss the generalizability (external validity) of the study results	- Discuss external validity to populations across relevant PROGRESS-Plus characteristics, considering issues of possible self-selection, healthy volunteer bias, losses across PROGRESS-Plus -Consider implications of exclusion of people across PROGRESS as well as differential participation and/or loss to follow-up - Consider context in discussion of generalizability
Other information			
Funding	22		

Section	Item No	Standard STROBE Checklist	Possible issues for STROBE equity extension (based on PRISMA-Equity and CONSORT-Equity reporting items)
		22. Give the source of funding and the role of the funders for the present study and, if applicable, for the original study on which the present article is based	
*Give information separately for cases and controls in case-control studies and, if applicable, for exposed and unexposed groups in cohort and cross-sectional studies.			